**Abstract**

**Introduction:** Little is known about patient characteristics and rehospitalization in newly diagnosed patients with schizophrenia treated with long-acting antipsychotics.

**Objectives:** To retrospectively explore hospitalizations, drug utilization and clinical outcomes from medical records of young, newly diagnosed schizophrenia patients during the first 12 months of treatment with once-monthly paliperidone palmitate (PP)

**Methods:** International, multicenter, retrospective, observational study. Outcomes presented are patient characteristics, reason for PP initiation and hospitalization data.

**Results**: 84 patients were analyzed: Mean age (years) at first psychotic episode was 23.8(SD2.6), 23.9(SD2.6) at first antipsychotic treatment and 24.1(SD2.7, range 19--29) at PP initiation. Time between first antipsychotic treatment and PP initiation was 4.8(SD3.4, range 0--12) months. At PP initiation 42.9% of patients were in hospital, primarily for the management of the first episode/relapse (97.2%). Reason for PP initiation was: LAT favored over oral treatment for relapse prevention (56%), partial/non adherence with previous oral medication (20.0%), convenience (15.5%) or limited access to health care systems (2.4%). Mean time (days) between admission and initiation of PP, and between initiation of PP and discharge from hospital was 28.8(SD23.0) and 23.2(SD24.5), respectively. 96.4% of patients were not hospitalized during the 12-month PP treatment period. 3/84 patients (3.6%) had a single hospitalization of 15.7(SD 8.1) days for management of episode/relapse.

**Conclusions:** In this young, newly diagnosed schizophrenia population the number of hospitalizations following PP initiation was low. Main reason to initiate PP was clinicians favoring LAT over oral antipsychotic treatment for relapse prevention or due to partial/non adherence with previous oral treatment.
